Evolus (EOLS) Projected to Post Quarterly Earnings on Wednesday

Evolus (NASDAQ:EOLS) is projected to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.01) per share and revenue of $81.5480 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Evolus (NASDAQ:EOLS) last announced its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $73.14 million during the quarter, compared to analysts’ expectations of $72.52 million. During the same period in the prior year, the company earned ($0.30) earnings per share. On average, analysts expect Evolus to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolus Stock Up 0.6%

EOLS opened at $6.22 on Wednesday. The stock has a market cap of $409.65 million, a PE ratio of -9.28 and a beta of 1.32. The business has a 50 day moving average of $6.49 and a 200-day moving average of $5.49. Evolus has a 52 week low of $3.86 and a 52 week high of $9.42.

Hedge Funds Weigh In On Evolus

Institutional investors and hedge funds have recently made changes to their positions in the business. Nantahala Capital Management LLC lifted its holdings in shares of Evolus by 1.6% during the fourth quarter. Nantahala Capital Management LLC now owns 5,820,649 shares of the company’s stock valued at $38,707,000 after purchasing an additional 93,792 shares during the last quarter. Caligan Partners LP boosted its position in shares of Evolus by 23.8% in the 3rd quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock worth $25,413,000 after purchasing an additional 796,973 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Evolus by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock worth $21,054,000 after buying an additional 110,693 shares during the last quarter. Braidwell LP purchased a new stake in shares of Evolus in the 4th quarter worth approximately $20,650,000. Finally, Soleus Capital Management L.P. grew its stake in shares of Evolus by 96.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after buying an additional 1,039,842 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on EOLS. BTIG Research reaffirmed a “buy” rating and issued a $13.00 price target on shares of Evolus in a research note on Wednesday, June 17th. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.00.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.